Psilocybin Therapy for Depression in Parkinson's Disease
Recruiting · NCT06455293 · Interventional (participants receive a specific treatment) · Lead sponsor: Joshua Woolley, MD, PhD
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Who can take part
Age range
40 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 40 to 80
- Comfortable speaking and writing in English
- Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
- Currently experiencing depressive symptoms
- Able to attend all in-person visits at UCSF as well as virtual visits
- Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating
Exclusion criteria
- Psychotic symptoms involving loss of insight
- Significant cognitive impairment
- Regular use of medications that may have problematic interactions with psilocybin
- A health condition that makes this study unsafe or unfeasible, determined by study physicians
Where it is running
1 location listed across 1 US state.
- University of California, San Francisco - San Francisco, California, United States